Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | CCR1 | P32246 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35212570 | 1.00 | SMN1; SMN2 (0.31) | SMN1; SMN2KMT2ATDP1MEN1CCR1 | |
| SCHEMBL35212289 | 0.92 | CFD (0.32) | SMN1; SMN2CCR1 | |
| SCHEMBL35211723 | 0.92 | CFD (0.32) | SMN1; SMN2CCR1 | |
| SCHEMBL35212013 | 0.90 | ALDH1A1 (0.32) | SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL35212167 | 0.90 | ALDH1A1 (0.32) | SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL35212554 | 0.90 | ALDH1A1 (0.32) | SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL35211825 | 0.90 | ALDH1A1 (0.32) | SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL35212432 | 0.90 | ALDH1A1 (0.32) | SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL35212159 | 0.89 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL35212574 | 0.89 | SMN1; SMN2 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | SMN1; SMN2 3863/4885KMT2A 4761/4885TDP1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.